Fundamental Data for DNA

GENENTECH(NYSE:DNA)

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. Genentech''s mission is to be the leading biotechnology company, using human genetic information to develop novel medicines for serious and life-threatening diseases.

# Employees: 11186

Address: 1 DNA Way,South San Francisco,CA,USA

Phone: 650-225-1000

Fax: 650-225-6000

Website: www.gene.com

Email: investor.relations@gene.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Arthur D. Levinson Ph.D. (Chmn.; C.E.O.)

Susan D. Desmond-Hellma nM.D. ()

M.P.HPresi. Product Develop. (Hal L. Barron M.D.)

David A. Ebersman (Exec. V.P.; C.F.O.,Stephen G. Juelsgaard J.D.,Exec. V.P.; Sec.; Chief Compliance Off.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 12/31/2008

Next Earnings Date(Expected): 4/9/2009

Mean EPS (Next Qtr): $0.83

Mean EPS (Year): $3.63

Mean Estimate(Long Term): $15.90

P/E Ratio(Based on EPS estimate): 26.110

Number of Estimates: 12

Shares Performance

Period	DNA	Compare to S&P
YTD	14.28 %	32.85 %
4 Weeks	9.64 %	3.04 %
12 Weeks	14.28 %	26.83 %

Shares Information

Analyst Coverage: Y

Avg Volume: 18262676

Shares Outstanding: 1053M

Market Cap: $99.85B

52 Week High: $98.81

52 Week Low: $67.24

P/E Ratio: 29.980

PEG Ratio: 1.640

Split: On 5/13/2004 DNA split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 21.62 %

EPS Growth in Last Year: 50.00 %

Sales Growth in Last Quarter: 8.65 %

Sales Growth in Last Quarter: 24.81 %

Financials

Qtr Book Value: $6.36

Cash Flow/Share: $23.91

Change in Payout Ratio: 0.000

Price/Sales: 7.440